 The purpose of this study is to compare the immune response, safety and reactogenicity of TritanrixTM-HepBHib-MenAC vaccine given either with or without a birth dose of hepatitis B vaccine to TritanrixTM-HepBHiberixTM when given to healthy infants born to mothers who do not carry hepatitis B virus at 6, 10 14 weeks of age. This study will also include a small group of infants born to mothers who do carry hepatitis B virus; these infants will receive a birth dose of hepatitis B vaccine and will be vaccinated with TritanrixTM HepBHib-MenAC at 6, 10 14 weeks age. 